The Department of Science and Technology (DOST) said Tuesday the emergency use of Pfizer’s vaccine candidate against Covid-19 is unlikely in the Philippines,
DOST Secretary Fortunato dela Pena said they need “to verify the accuracy of (Pfizer’s) claim that the vaccine is 90 percent effective. If (Pfizer) will apply to conduct a clinical trial here, the Vaccine Expert Panel will check the data, and would verify the claim,” he added during the recent Laging Handa public briefing.
Pfizer announced last Monday its candidate vaccine was found to be “more than 90% effective in preventing Covid-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis.”
Pfizer plans to submit an Emergency Use Authorization to the US Food and Drug Administration (FDA) by the third week of November. Its announcement was based on a Phase 3 clinical study. De la Peña the Philippines requires Phase 4 clinical trials for the vaccine candidates.
The DOST chief noted that Philippine authorities could not rely on Pfizer’s announcement, since it was the firm’s pwn. “We do not know the data that supports the claim,” he said.
He added that in case Pfizer would not conduct a clinical trial in the Philippines and would submit an application to the Philippine FDA for supply purposes, that would still be referred to the Vaccine Expert Panel for analysis.
De la Peña said there is no date yet as to when the World Health Organization (WHO) Solidarity Vaccine Trial for Covid-19 would commence. “As of November 10, we have not received the list of vaccines and the protocols from the WHO,” he shared.
WHO’s protocols would include the age group of clinical trial participants, the number of doses, and the required temperature for storage, among others, de la Peña said.